Use access key #2 to skip to page content.
$5.85 0.03 (0.52%)
7/23/2008 4:00 PM

Dendreon Corp (DNDN)

CAPS Rating:
**

A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.

View All Commentary (DNDN)

Recs

9

Avatar tomk0508 (92.93) Submitted: 2/03/08 11:19 PM : Outperform Start Price: $6.30 DNDN Score: 0.76

This company is sitting on a blockbuster advance in treatment of late stage prostrate cancer. The compound is a biologic and therefore is a bit of a political football with the FDA. Fortunately, the drug is relatively harmless and very effective for cases that have been unresponsive to other treatments. The company's recent promotion of Froelich to Chief Medical Officer shows they are earnest about changing the relationship with the FDA. The near term may be ugly but by late 2008 the outperform rating will be clear to all.

Report this Post Replies: 0 | Reply

Featured Broker Partners